摘要
目的:探讨沙库巴曲缬沙坦对比传统血管紧张素转化酶抑制剂(ACEI)和血管紧张素Ⅱ受体拮抗剂(ARB)类药物对老年心力衰竭患者的临床疗效及其对血清中可溶性ST2(sST2)、血管紧张素Ⅱ(AngⅡ)、N末端脑钠肽前体(NT-proBNP)、血清肌酐(SCr)及肾小球滤过率(eGFR)的影响。方法:选取2018-04-2019-01于蚌埠医学院第一附属医院心内科就诊的老年心力衰竭患者,随机分为两组,其中观察组为接受沙库巴曲缬沙坦治疗者52例,对照组为接受传统ACEI/ARB药物治疗者60例,分别对两组患者进行约6个月的随访,对比两组患者治疗前后左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内经(LVESD),血清指标NT-proBNP、sST2、AngⅡ,以及肾脏功能指标SCr、eGFR。结果:与治疗前相比较,两组患者治疗后LVEF、LVEDD、LVESD、NT-proBNP、sST2及AngⅡ均有所改善,且观察组改善程度明显优于对照组(均P<0.05);两组患者治疗后肾脏功能指标SCr与eGFR均较治疗前改善(均P<0.05),且观察组SCr较对照组改善更为明显(P<0.05)。结论:沙库巴曲缬沙坦治疗老年心力衰竭临床疗效较传统药物有明显优势,可明显改善患者心脏功能,抑制心肌重构,且能更好地改善血清学指标。
Objective:To compare the clinical efficacy of sacubiltrril/valsartan with traditional ACEI and ARB drugs in elderly patients with heart failure and to investigate its effects on soluble ST2,AngⅡ,NT-proBNP,SCr and eGFR in serum.Method:The elderly patients with heart failure in the Department of Cardiology,the First Affiliated Hospital of Bengbu Medical College from April 2018 to January 2019 were randomly divided into two groups.Fifty-two patients treated with sakubatra/valsartan were included into observation group,and 60 patients treated with traditional ACEI/ARB drugs were included into control group.All patients were followed up for about 6 months.Left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic menstruation(LVESD),NT-proBNP,sST2,AngⅡ,SCr,and eGFR before and after treatment were compared between control group and observation group.Result:Compared with before treatment,LVEF,LVEDD,LVESD,NT-proBNP,sST2 and AngⅡ in the two groups were improved after treatment,and the improvement degree in the observation group was significantly better than that in the control group(all P<0.05).The renal function indexes SCr and eGFR in the two groups were improved after treatment(all P<0.05),and SCr in the observation group was improved more obvious than that in the control group(P<0.05).Conclusion:Sakubatril/valsartan has obvious advantages over traditional drugs in the treatment of elderly heart failure.It can improve cardiac function,inhibit myocardial remodeling, and improve serological indexes.
作者
张维
张先林
康品方
钱少环
张恒
ZHANG Wei;ZHANG Xianlin;KANG Pingfang;QIAN Shaohuan;ZHANG Heng(Department of Cardiology,First Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui,233000,China)
出处
《临床心血管病杂志》
CAS
北大核心
2019年第12期1145-1148,共4页
Journal of Clinical Cardiology
基金
安徽省科技攻关项目(No:1804h08020246)
安徽省高等学校自然科学研究重点项目(No:KJ2019A0401)
